<qa>  What is the clinical program that studies the efficacy, safety, and tolerability ofWhile the Lisdexamfetamine Dimesylate SPD489 clinical program has studied the efficacy, safety, and tolerability of SPD489 in treating core symptoms of ADHD in children and adolescents aged 6-17 years and adults aged 18-55 years, the majority of these studies have been of short duration - up to 8 weeks. 